Key Highlights
● Iovance raised 2026 Revenue guidance to $410 million to $420 million from $350 million to $370 million on U.S. demand.
● Summit surged to close at $17.96 after AstraZeneca agreed to a $2 billion strategic Equity Investment with no license attached.
● uniQure collapsed after 48-month Huntington's data showed slowing of disease progression that was not statistically significant.
● Healthcare stocks declined overall at midday, and the 30-year Treasury Yield reached its highest level since 2002.
Biotech investors got a reminder of how quickly fortunes can swing on Tuesday, September 29, 2026. Iovance Biotherapeutics and Summit Therapeutics posted some of the biggest gains in the market, while uniQure collapsed on disappointing clinical data.
Iovance Raises the Bar
Iovance Biotherapeutics (NASDAQ:IOVA) soared after raising its full-year 2026 total revenue guidance to $410 million to $420 million, from $350 million to $370 million, citing strong U.S. Demand for Amtagvi and Proleukin. One source had the shares at about $15 during the session, with sources differing on the size of the rally. Interim President and CEO Frederick Vogt said increasing patient demand and the current Manufacturing schedule provide strong visibility.
Summit Lands AstraZeneca
Summit Therapeutics (NASDAQ:SMMT) surged to close at $17.96 after AstraZeneca agreed to make a $2 billion strategic equity investment. AstraZeneca will buy convertible preferred stock at $18.36 per common share, a premium to Summit's recent average price, and the companies will collaborate on cancer studies. Sources differed on the size of the gain. Stifel noted there is no license, so Summit keeps full ivonescimab Economics in its territories, and BMO Capital Markets said the deal creates a meaningful strategic position without acquiring the company or licensing the drug outright at this stage.
uniQure's Setback
uniQure (NASDAQ:QURE) collapsed after releasing 48-month Phase I/II data for AMT-130, its gene therapy for Huntington's disease. One source had the shares at about $25 in the session, after much steeper declines in premarket trading. High-dose patients showed slowing of disease progression on the cUHDRS measure, but the result was not statistically significant, and the slowing was smaller than at the 36-month mark.
The FDA had said 36-month data would underpin the company's application for approval. Management defended the results, and its chief executive said the comparison group increasingly reflected a healthier population than at baseline. ClearPoint Neuro (NASDAQ:CLPT), whose platform is used to deliver AMT-130, tumbled in sympathy.
A Mixed Sector Backdrop
Healthcare stocks declined overall at midday. Other biotech news included Immix Biopharma's interim data for its CAR-T therapy NXC-201 in AL amyloidosis and a post hoc analysis of Vor Bio's telitacicept in myasthenia gravis. The major indexes finished lower, with the S&P 500 down 12.85 points at 7,670.84 and the Dow Jones Industrial Average down 131.59 points at 51,349.92. The Nasdaq Composite ended nearly flat at 26,797.54. The Russell 2000, home to many small biotechs, finished lower, and the 30-year yield's climb is a headwind for cash-hungry drug developers.
Regulatory Detail Investors Want
Investors will look for more detail from uniQure on its regulatory path and from Summit and AstraZeneca on their clinical collaboration. For the wider market, Wednesday, September 30, brings August PCE Inflation and the third GDP estimate. The September jobs report follows Friday, October 2, and the Fed meets October 27 to 28.






Please wait processing your request...